GLPwatch
Hair loss
3,828 FAERS reports across 8 drugs
Last updated 2026-05-28 15:46 UTCHair loss is the thinning or falling out of hair from the scalp or other parts of the body.
Plain-language definition of the term.
FDA labels for Byetta, Mounjaro, Ozempic, Rybelsus, Saxenda, Soliqua, Wegovy, Xultophy, and Zepbound list hair loss as an adverse reaction reported in clinical trials.
AI summary of the sources below.
FAERS report counts (as of 2026Q1) reflect voluntary adverse-event reports and cannot establish causation or true frequency; higher counts often track prescription volume. openFDA FAERS ↗
Reports by drug
| Drug | FAERS reports | Quarter |
|---|---|---|
| Zepbound | 1,128 | 2026Q1 |
| Mounjaro | 962 | 2026Q1 |
| Ozempic | 710 | 2026Q1 |
| Trulicity | 416 | 2026Q1 |
| Victoza | 344 | 2026Q1 |
| Wegovy | 128 | 2026Q1 |
| Saxenda | 87 | 2026Q1 |
| Rybelsus | 53 | 2026Q1 |
Mentioned in FDA labels
Research mentioning hair loss (11)
- Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023.
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.
- Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study.
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review.
- Glucagon-like peptide-1 receptor agonists and hair loss: An emerging clinical concern.
- Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis.
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.
- Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review.
- Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review.
- Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study.
- Impact of GLP-1 and GLP-1/GIP agonists on healthcare resource utilization in individuals with scarring alopecias: A retrospective cohort analysis using TriNetX.